Levy J, Klastensky J
J Clin Pharmacol. 1975 Oct;15(10):705-7. doi: 10.1002/j.1552-4604.1975.tb05924.x.
The half-life of amikacin in serum has been measured following the administration of a single intravenous injection of 7 mg/kg in nine adult patients with varying degrees of renal function impairment and in four patients with normal renal function. A linear relationship between the half-life and the serum concentration has been found, suggesting that half-life of amikacin in serum can be calculated by multiplying the serum creatinine (in mg/100 ml) by 3.